On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
On Dec. 9, 2022, Washington University in St. Louis announced that it’s nasal COVID-19 vaccine technology had been…
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
On Nov. 18, 2022, the Journal of the American Medical Association reported that the U.S. experienced high COVID-19…
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
On Nov. 9, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
On Nov. 1, 2022, the National Institutes of Health (NIH) announced that adults with hypertension saw a small,…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
On Oct. 25, 2022, the University of Washington reported that daily global COVID-19 infections were projected to rise…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyﾒs (EMA) Committee for Medicinal Products…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…